Welcome back to our blog at Stem Cell Therapy Argentina®! As leaders in regenerative medicine, we always strive for transparency in our practices so that our patients understand the decisions we make. Today, we want to address a common question: why don’t we incorporate umbilical cord-derived mesenchymal stem cells or exosomes into our treatments? The answer lies in our unwavering commitment to patient safety, regulatory compliance, and proven scientific evidence. Let’s break it down step by step.
Our Focus on FDA-Authorized Products
A fundamental pillar of our philosophy is to not work with products that have not yet been authorized by the FDA (U.S. Food and Drug Administration). Although umbilical cord cells and exosomes show promise in preliminary research, many of these approaches are still in experimental phases and have not passed the rigorous safety and efficacy testing required by the FDA for widespread use.
The FDA sets global standards for biosafety and effectiveness, and adhering to them allows us to offer treatments supported by solid evidence. Instead of rushing into unproven innovations, as some medical centers do to profit, at Stem Cell Therapy Argentina® we opt for methods that have demonstrated consistent results in clinical studies and comply with the strictest international regulations.
The Risks of Importation and Biosecurity
Even if we were to consider importing these products from other countries, we would face significant barriers. Any import of umbilical cord mesenchymal stem cells or exosomes requires specific customs clearance authorization issued by Argentine authorities. Without this approval, not only are import laws violated, but serious biosafety risks are also posed.
Imported biological products can be damaged during transport, such as by exposure to unsuitable temperatures or contaminants, which could compromise their integrity and ultimately affect patient health. Problems such as infections, unpredictable immune reactions, or therapeutic inefficacy are real concerns in these cases. At Stem Cell Therapy Argentina®, we avoid these scenarios by focusing on safe, local solutions that do not rely on vulnerable international supply chains.
Our Safe Alternative: Autologous Treatments with the Patient’s Own Cells
Given these regulatory and safety challenges, we have opted for an autologous approach, using cells and derivatives from the patient’s own body. This not only eliminates the risk of immune rejection but also ensures full compliance with current regulations and medical practice. Here’s how we do it:
- Same-day harvested cells: We extract mesenchymal stem cells from the patient’s adipose tissue during the outpatient procedure. These are processed immediately and reinjected, minimizing any external manipulation and maximizing freshness and viability.
- Expanded Cells Under GMP Conditions: For cases requiring a larger number of cells, we expand them in laboratories certified under Good Manufacturing Practices (GMP). This guarantees sterility, purity, and traceability, all within a regulated framework.
- Hyperconcentrated Platelet-Rich Plasma (PRP): Obtained directly from the patient’s blood on the same day, the PRP is concentrated into high doses and reinjected to enhance regeneration. It is a simple, effective, and approved method, ideal for treating conditions such as osteoarthritis without the need for surgery.
These treatments have benefited thousands of patients at our clinics in Buenos Aires, Mendoza, and Córdoba, with proven results in pain reduction, improved mobility, and tissue regeneration. Under the direction of Dr. Matías Fernández Viña, who gives global lectures on these protocols, we maintain an ethical and scientific approach that prioritizes your well-being.
Conclusion: Safety First
In summary, at Stem Cell Therapy Argentina® we do not use umbilical cord mesenchymal stem cells or exosomes because there is no current authorization for their use in Argentina, regulations are lacking to validate their use, and they do not comply with FDA approvals. Furthermore, importing them carries biosafety risks that could affect patients. Instead, we focus on safe, effective, and regulated autologous treatments, using the patient’s own cells for optimal results, with strong scientific backing worldwide.
If you have any questions about our treatments or would like to schedule a consultation, please contact us! Subscribe to our blog for more insights on regenerative medicine.
Stem Cell Therapy Argentina – Safety and regeneration, hand in hand.
